Monthly Investment Breakdown: Planning Your Treatment Budget
Ozempic vs Wegovy vs Mounjaro: Understanding UK Monthly Costs
When comparing Ozempic vs Wegovy vs Mounjaro monthly costs, it's crucial to understand that only Wegovy and Mounjaro are licensed for weight management in the UK. Ozempic, while containing the same active ingredient as Wegovy (semaglutide), is licensed exclusively for type 2 diabetes treatment. This means legitimate UK pharmacies cannot prescribe Ozempic for weight management purposes. Wegovy costs start at £79.99 monthly for the initial 0.25mg dose, escalating through a structured 16-week programme to reach the maintenance dose of 2.4mg at £209.99 monthly.
Mounjaro (tirzepatide) represents a newer dual-action medication combining GIP and GLP-1 receptor activation, with its own pricing structure that differs from Wegovy's semaglutide-based approach. The monthly investment for either prescription-only medicine requires careful budgeting consideration, as both medications work alongside a reduced-calorie diet and increased physical activity. Understanding these ongoing costs helps patients make informed decisions about their long-term weight management commitment.
Wegovy Monthly Pricing Structure and Value Investment
The Wegovy dose escalation creates a predictable monthly cost progression: £79.99 (weeks 1-4), £94.99 (weeks 5-8), £99.99 (weeks 9-12), £139.99 (weeks 13-16), reaching maintenance at £209.99 monthly from week 17 onwards. New customers benefit from the FIRST40 discount code applied at checkout, while returning customers use DOSE25 for continued value. These prices reflect the final cost after discount application, eliminating surprise charges or hidden subscription fees.
Our Getting Started bundles provide convenience for planning multiple months ahead, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 covering your first 8 weeks. The Ultimate Stability Trio provides three months of maintenance supply (2.4mg ×3) for £649.99, helping established patients manage their ongoing investment efficiently. Each bundle includes the same pharmaceutical-grade Wegovy from Novo Nordisk, delivered via our GPhC-registered pharmacy service (#9012878).
Clinical Evidence Supporting Ozempic vs Wegovy vs Mounjaro Investment Decisions
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated sustained benefits when patients maintained their treatment regimen, with STEP 5 showing approximately clinically studied weight loss maintained at 2 years. These outcomes help justify the monthly investment when viewed as part of comprehensive weight management.
Mounjaro's clinical profile emerges from different trial populations and methodologies, making direct percentage comparisons inappropriate. Both medications represent significant monthly investments, but the clinical evidence suggests potential for meaningful health outcomes when used as prescribed. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events with semaglutide, adding potential long-term health economic value to the monthly cost consideration.
How Wegovy's Mechanism Justifies Monthly Investment
Wegovy functions as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. This mechanism may help reduce food cravings by working on brain appetite centres, potentially supporting behaviour changes that complement the monthly medication investment. The once-weekly FlexTouch pen delivery system ensures consistent therapeutic levels throughout each dosing period, maximising the clinical value of your monthly cost. Unlike daily medications requiring multiple monthly supplies, Wegovy's weekly dosing means each monthly pen purchase provides four complete therapeutic doses. The sophisticated delivery mechanism and pharmaceutical precision justify the premium pricing structure compared to basic weight management supplements.
Streamlined Ordering Process Maximising Your Investment
Our 3-minute online clinical assessment initiates your treatment journey, followed by prescriber review typically completed within 3 working days (or express 24-hour service available). Once approved, next-day delivery ensures your monthly investment reaches you safely via cold-chain, temperature-controlled logistics maintaining pharmaceutical integrity. The streamlined process minimises delays that could disrupt your treatment schedule, protecting the continuity essential for optimal clinical outcomes. Our GPhC-registered pharmacy operations (#9012878) ensure every monthly supply meets UK pharmaceutical standards, giving confidence in your ongoing investment.
Storage Requirements and Practical Cost Considerations
Wegovy requires refrigeration at 2-8°C before first use but offers significant storage flexibility with 6 weeks room temperature stability below 30°C once removed from refrigeration. This storage advantage over Mounjaro's 21-day room temperature limit provides practical value, especially for travel or lifestyle flexibility that protects your monthly investment. The FlexTouch pen design delivers precise doses throughout the escalation schedule, ensuring you receive full therapeutic value from each monthly purchase. Proper storage maintains medication potency, preventing waste that would impact your monthly budget planning. Understanding these practical aspects helps maximise the clinical and economic value of your ongoing treatment investment.
Long-term Budget Planning for Ozempic vs Wegovy vs Mounjaro UK Costs
Annual maintenance costs for Wegovy at the 2.4mg dose total approximately £2,520 yearly (£209.99 × 12 months), representing a significant but structured health investment. The 16-week escalation period requires approximately £514 total investment before reaching maintenance dosing, helping patients budget for the initial treatment phase. Returning customers benefit from the DOSE25 discount code ensuring predictable monthly costs without surprise price increases.
Planning for potential treatment duration requires understanding that weight management represents a long-term commitment, as clinical data shows patients typically regain approximately two-thirds of weight lost within one year of stopping treatment. This context helps frame the monthly investment as part of ongoing health maintenance rather than short-term expense. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to help determine which monthly cost structure aligns best with your clinical needs and budget planning.
Complete Treatment Investment with EverydayMeds Support
Your monthly investment includes comprehensive support beyond just medication supply, encompassing clinical assessment, prescriber review, pharmaceutical dispensing, and temperature-controlled delivery logistics. New customers can begin their journey using code FIRST40 at checkout, while established patients maintain value with DOSE25 for ongoing supplies. Our transparent pricing eliminates surprise charges, subscription traps, or hidden fees that complicate monthly budgeting for weight management treatment. Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to explore dose options and bundle packages suited to your treatment timeline. The investment in prescription-only medicine through our GPhC-registered service (#9012878) ensures pharmaceutical quality, clinical oversight, and ongoing support throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
